{"entity":{"id":"investigational-new-drug-application","kind":"term","name":"Investigational New Drug application","aka":["IND application","Investigational New Drug","investigator IND"],"tldr":"This application supports a specified investigation or treatment-access use of a drug in the United States. It is separate from permission to market the product.","summary":"An Investigational New Drug application contains nonclinical, manufacturing and clinical-protocol information for defined investigational use. Becoming effective does not establish that the product benefits a person or is approved for marketing, and a clinical hold can prevent use. A New Drug Application or Biologics License Application instead requests marketing authorization. Submission, acceptance for filing, an application becoming effective and a marketing decision are different events. The applicable route and product version matter.","asOf":"2026-11-11","links":[{"label":"FDA: Investigational New Drug application","url":"https://www.fda.gov/drugs/types-applications/investigational-new-drug-application-ind"},{"label":"FDA: new drug applications","url":"https://www.fda.gov/drugs/types-applications/new-drug-application-nda"},{"label":"FDA: biologics license applications","url":"https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-blas-cber-regulated-products"},{"label":"FDA: expanded access questions and answers, April 2026","url":"https://www.fda.gov/media/162793/download"}],"tags":[],"related":["bla-nda","first-in-human","expanded-access","investigator-initiated-trials","trial-protocol"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["For an ordinary new IND, FDA describes a 30-calendar-day period after receipt before an investigation may begin, unless FDA gives earlier notification or imposes a hold. Expanded-access INDs and protocols have route-specific rules; no application number establishes a treatment start date.","Product identity matters alongside the proposed use. A redesigned cell product or personalised formulation cannot acquire another product's evidence or authorisation merely by sharing a target, ingredient category or platform name. FDA assesses nonclinical, manufacturing and clinical-protocol information for the proposed investigation. Ask whether the cited data and permission actually cover that product version and plan; a supplier's earlier authorisation is not itself permission for a different use."],"category":"Regulation & policy"},"route":"/terms/investigational-new-drug-application/","neighbours":{"term":[{"id":"bla-nda","kind":"term","name":"BLA / NDA / MAA (marketing applications) and PDUFA dates","route":"/terms/bla-nda/"},{"id":"trial-search-site-verification","kind":"term","name":"Clinical trial search, site verification and screening","route":"/terms/trial-search-site-verification/"},{"id":"expanded-access","kind":"term","name":"Expanded access (compassionate use)","route":"/terms/expanded-access/"},{"id":"fast-track-rmat","kind":"term","name":"Fast Track and RMAT designations","route":"/terms/fast-track-rmat/"},{"id":"first-in-human","kind":"term","name":"First-in-human (FIH) trial","route":"/terms/first-in-human/"},{"id":"investigator-initiated-trials","kind":"term","name":"Investigator-initiated trials and study responsibilities","route":"/terms/investigator-initiated-trials/"},{"id":"label-indication","kind":"term","name":"Label, indication and label expansion","route":"/terms/label-indication/"},{"id":"off-label","kind":"term","name":"Off-label","route":"/terms/off-label/"},{"id":"right-to-try","kind":"term","name":"Right to Try Act 2018 and state right-to-try laws","route":"/terms/right-to-try/"},{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/"}]}}